Investor Relations

Corporate Profile

Corporate Profile

QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.

Ranked among the world’s largest in vitro diagnostics (IVD) providers, QuidelOrtho is building on more than 120 years of collective experience and innovation. We combine industry-leading expertise in immunoassay and molecular testing with a global footprint in point-of-care settings, clinical labs and transfusion medicine to advance critical diagnostic solutions at scale.

Read More

Recent News

View All News

Recent and Upcoming Events

View All Events

Investor Presentation

Quarterly Results

View All Quarters

Archived financial results

Analyst Coverage

Firm Analyst Phone
Citi Patrick Donnelly 212-816-0701
Craig-Hallum Capital Group Alex Nowak, CFA 612-334-6347
J.P. Morgan Casey Woodring 212-622-9074
Nephron Research Jack Meehan, CFA 646-214-0299
Raymond James Andrew Cooper 727-567-2295
RBC Capital Markets Conor McNamara, CFA 619-782-5265
UBS  Elizabeth Garcia  212-713-2697 
William Blair Andrew Brackmann, CFA 312-364-8776

As of December 2022, QuidelOrtho Corporation is aware that it is followed by the analysts listed above; however, it is possible that the list above is not complete. Please note that any opinions, estimates or forecasts regarding QuidelOrtho Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of QuidelOrtho Corporation or its management. QuidelOrtho Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Interactive Analyst center

Income Statements (in millions, except per share amounts)

View more details